# Methotrexate Sodium Injection: FDA shortage status

> FDA source status only. Nationwide status is not local pharmacy inventory. This page does not provide medical, treatment, substitution, or dosing advice.

- Derived status: current
- Source statuses: Current
- FDA package records: 14
- Latest FDA row update: 08/17/2026
- Retrieved: 2026-08-22T15:54:11+00:00

## FDA package and manufacturer records

- Accord Healthcare Inc. — Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) — FDA availability: Available — updated: 08/17/2026
- Accord Healthcare Inc. — Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) — FDA availability: Available — updated: 08/17/2026
- Fresenius Kabi USA, LLC — Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) — FDA availability: Available — updated: 08/04/2026
- Fresenius Kabi USA, LLC — Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) — FDA availability: Available — updated: 08/04/2026
- Hikma Pharmaceuticals USA, Inc. — Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) — FDA availability: Unavailable — updated: 08/13/2026
- Hikma Pharmaceuticals USA, Inc. — Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) — FDA availability: Available — updated: 08/13/2026
- Hospira, Inc., a Pfizer Company — Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) — FDA availability: Available — updated: 08/07/2026
- Hospira, Inc., a Pfizer Company — Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) — FDA availability: Available — updated: 08/07/2026
- Hospira, Inc., a Pfizer Company — Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) — FDA availability: Available — updated: 08/07/2026
- Hospira, Inc., a Pfizer Company — Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10) — FDA availability: Available — updated: 08/07/2026
- Hospira, Inc., a Pfizer Company — Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) — FDA availability: Available — updated: 08/07/2026
- Teva Pharmaceuticals USA, Inc. — Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) — FDA availability: Unavailable — updated: 08/17/2026
- Teva Pharmaceuticals USA, Inc. — Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) — FDA availability: Unavailable — updated: 08/17/2026
- Teva Pharmaceuticals USA, Inc. — Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) — FDA availability: Unavailable — updated: 08/17/2026

## Sources and formats

- [FDA openFDA source](https://api.fda.gov/drug/shortages.json)
- [Canonical HTML](https://citefacts.com/shortages/methotrexate-sodium-injection)
- [JSON record](https://citefacts.com/shortages/methotrexate-sodium-injection.json)